M
MXCT
Maxcyte
0.7535
+0.0435+6.13%After Hours: 0.7685 +0.0150 +1.99%19:06 04/08 EDT
OPEN/PREV CLOSE0.7400/0.7100
TODAY RANGE0.7200-0.7594
VOL804.47K
MARKET CAP80.52M
52 WEEK RANGE0.6434-2.955
AVG VOL (3M)1.20M
% TURNOVER0.75%
TURNOVER--
P/E (TTM)-1.7970
% RANGE5.18%
EPS(TTM)-0.4193
P/E(FORWARD)-2.8434
P/B0.4692
BVPS1.606
DIVIDEND--
P/S2.436
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP75.40M
SHARES OUTSTANDING106.86M
NEXT EARNINGS05/04-05/18
FREE FLOAT100.06M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Reuters·03/31 20:07
MaxCyte grants CFO Parmeet Ahuja 375,000 stock options under inducement plan
Reuters·03/31 20:05
MAXCYTE REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
TipRanks·03/27 22:10
MaxCyte Appoints New Chief Financial Officer Ahuja
TipRanks·03/27 00:18
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
Dow Jones·03/25 16:34
MaxCyte Is Maintained at Buy by Craig-Hallum
Dow Jones·03/25 16:34
MaxCyte Price Target Cut to $5.00/Share From $7.00 by Craig-Hallum
Benzinga·03/25 16:24
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5
TipRanks·03/25 13:41
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
Seeking Alpha·03/25 06:15
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook
NASDAQ·03/24 21:35
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
TipRanks·03/24 20:55
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
Same Industry
Name/Symbol
Change%
Price